BIOCARD
The overarching goal of the BIOCARD Study is to improve understanding of the earliest phases of Alzheimer’s disease (AD). The domains of information collected as part of the study include: clinical and cognitive evaluations, blood specimens, cerebrospinal fluid (CSF), magnetic resonance imaging (MRI) scans, amyloid imaging using positron emission tomography (PET), and Tau PET imaging.
Study Participants
The participants in the BIOCARD study were all cognitively unimpaired and primarily middle-age when first enrolled. The study began in 1995 and was transferred to Johns Hopkins University in 2009, where it continues to the present time. Each annual visit includes assessments of participants' clinical and cognitive status and blood collection. The collection of MRI scans, amyloid PET scans, Tau PET scans and CSF occurs approximately every other year. The BIOCARD Study continues to follow participants who were initially enrolled at the NIH and is now also enrolling new participants.
Available Data
Cognitive test scores, Clinical data, Consensus Diagnoses, Genetic data, Magnetic Resonance Imaging scans and measurements, Amyloid imaging scan measurements (using PiB), Tau imaging scan measurements (using MK6240), Blood measurements, Cerebrospinal fluid values, Neuropathology data. Requests for additional data or other sample types can be placed here: www.biocard-se.org.
Available Biospecimens
Cell Line DNA, Genomic DNA